Evaluation of aprepitant for acute chemotherapy‐induced nausea and vomiting in children and adolescents with acute lymphoblastic leukemia receiving high‐dose methotrexate

Felix-Ukwu, Femi; Reichert, K; Bernhardt, M. Brooke; Schafer, Eric S.; Berger, Amanda

doi:10.1002/pbc.26857

Cited by 9 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is limited information on nausea/vomiting in hematologic diseases, particularly concerning CINV in ALL. Nausea is managed with prophylactic antiemetics (ondansetron, granisetron, or metoclopramide) administered intravenously or orally before and during chemotherapy [10,116,117].…”

Section: Cinv In Acute Lymphoblastic Leukemia Patientsmentioning

confidence: 99%

See 1 more Smart Citation

A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches

Bossi

Airoldi

Spiriti

et al. 2020

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: A range of combination chemotherapy regimens are currently used in clinical practice. However, international antiemetic guidelines often only categorize the emetogenic potential of single agents rather than the emetogenicity of combination chemotherapy regimens. To manage the nausea and vomiting induced by antineoplastic combinations, guidelines suggest antiemetics that are appropriate for the component drug with the highest emetogenic potential. Furthermore, antiemetic guidelines generally do not consider the influence of other factors, including individual patient characteristics, on the emetic effects of cancer treatments. Similarly, the emetogenic potential of radiotherapy is stratified only according to the site of radiation, while other factors contributing to emetic risk are overlooked. Areas covered: An Expert Panel was convened to examine unresolved issues and summarize the current clinical research on managing nausea and vomiting associated with combination chemotherapy and radiotherapy. Expert opinion: The panel identified the incidence of nausea and vomiting induced by multi-drug combination therapies currently used to treat cancer at different anatomic sites and by radiotherapy in the presence of other risk factors. Based on these data and the clinical experience of panel members, several suggestions are made for a practical approach to prevent or manage nausea and vomiting due to chemotherapy regimens and radiation therapy.

show abstract

Section: Cinv In Acute Lymphoblastic Leukemia Patientsmentioning

confidence: 99%

“…The ondansetron and aprepitant combination appears to be effective at preventing nausea and vomiting in patients undergoing multiday moderately/highly emetogenic chemotherapy [10,116,117].…”

Section: Cinv In Acute Lymphoblastic Leukemia Patientsmentioning

confidence: 99%

A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches

Bossi

Airoldi

Spiriti

et al. 2020

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…Chemotherapy-induced nausea and vomiting are prevalent and detrimental side effects of cancer treatment [7,29,30]. Approximately 60% of patients under chemotherapy despite receiving antiemetic medications have experienced nausea and vomiting.…”

Section: Preoperative Anesthetic Assessmentmentioning

confidence: 99%

“…Approximately 60% of patients under chemotherapy despite receiving antiemetic medications have experienced nausea and vomiting. Recommendations for the prevention of nausea and vomiting were dexamethasone, ondansetron, and chlorpromazine [29,30].…”

Section: Preoperative Anesthetic Assessmentmentioning

confidence: 99%

General Anesthesia for Pediatric Patients with Leukemia

Tsukamoto

Taura

Yamanaka

et al. 2019

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Pediatric leukemia is a common cause of disease-related fatality in children aged 1 to 10 years. This disease is usually treated with a combination of chemotherapy, radiation therapy, and bone marrow transplantation. With advancements in cancer treatment, approximately 70-80% of pediatric cancer patients have been cured with these aggressive combination therapies. However, oral and dental infection, mucositis, and necrosis of tissues can occur during the cancer treatment, which may lead to morbidity and an inferior quality of life for pediatric patients with leukemia. Early detection and radical treatment reduce the risk of oral infection and its associated systemic complications. Moreover, dental treatment such as extraction or preventive treatment of teeth should be considered before the start of the cancer treatment. However, it is difficult to provide dental treatment to pediatric patients with leukemia in usual settings due to their uncooperative behavior and/or the presence of psychiatric disorders. Therefore, general anesthesia during dental treatment is often recommended for these patients. In this paper, we reviewed the anesthetic management and perioperative complications in pediatric patients with leukemia receiving general anesthesia.

show abstract

“…Kemoterapiye bağlı bulantı-kusma çocuklarda %60'ın üzerinde en yaygın görülen ve multidisipliner yaklaşım gerektiren semptomlar arasındadır. Son yıllarda antiemetik tedavi protokolleriyle ilgili gelişmelere rağmen, bulantı-kusmayla baş etme güçlükleri hala devam etmektedir [1][2][3]. Bulantı-kusmanın etkin yönetimine ilişkin yetişkin bireylerde kanıt temelli rehberler bulunmaktadır.…”

Section: Introductionunclassified

Symptom Management for Nausea-Vomiting in Children Receiving Cancer Treatment: Evidence-Based Practices

Gürcan¹,

Turan²

2019

jcp

View full text Add to dashboard Cite

Kemoterapiye bağlı oluşan bulantı-kusma kanser tedavisi alan çocuklarda en yaygın görülen ve multidisipliner yaklaşım gerektiren semptomlar arasındadır. Son yıllarda antiemetik tedavi protokolleriyle ilgili gelişmelere rağmen, bulantı-kusmayla baş etme güçlükleri günümüzde hala devam etmektedir. Kontrol altına alınamayan bulantı-kusma deneyimleyen çocuklar, tedavi sürecinde uzama, yaşam kalitesinde azalma, sıvı-elektrolit dengesizliği, yetersiz beslenme ve tedaviye uyumda azalma gibi birçok sorun yaşamaktadır. Bu derlemede, çocuklarda bulantı-kusmaya yönelik kanıta dayalı, güncel ve güvenilir bilgilerin hemşireler için rehber niteliği taşıması amaçlanmıştır. Bulantıkusmayı azaltmak için farmakolojik yöntemlerin yanında integratif sağlık yaklaşımları da tercih edilmektedir. Hemşireler bulantı-kusmanın optimal düzeyde yönetilmesini sağlamak için yeterli bilgiye ve donanıma sahip olmalıdır. Bu doğrultuda, kanıta dayalı tedavileri uygulama ve integratif yöntemlerle ilgili rehberlik/danışmanlık yapmalı ve eğitim vermelidir. Bunun yanında, uygulama rehberlerini takip ederek, değişen bilgiler doğrultusunda klinik uygulamalarını güncelleştirmelidir.Kemoterapi protokollerine uygun standart, güncel antiemetik tedavilerin uygulanması çocukların yaşadığı bulantı-kusma semptomunun önlenmesini/azaltılmasını sağlayarak çocuk ve ebeveynlerin yaşam kalitesini arttıracaktır. Bu derlemede, bulantı-kusma yönetiminde uygulanan değerlendirme araçları ve standart tedavi yöntemlerinin yetersiz olduğu belirlenmiştir. Bu nedenle, bulantı-kusmanın etkin yönetilmesi için hem farmakolojik hem integratif yöntemlerle ilgili daha fazla deneysel ve kanıta dayalı çalışmaların yapılması önerilmektedir.

show abstract

Evaluation of aprepitant for acute chemotherapy‐induced nausea and vomiting in children and adolescents with acute lymphoblastic leukemia receiving high‐dose methotrexate

Cited by 9 publications

References 10 publications

A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches

A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches

General Anesthesia for Pediatric Patients with Leukemia

Symptom Management for Nausea-Vomiting in Children Receiving Cancer Treatment: Evidence-Based Practices

Contact Info

Product

Resources

About